Sort
48,018 grants matching “immunotherapy”
CELL MEDIATED IMMUNE RESPONSE TO INTRAOCULAR TUMORS
$372,000Schepens Eye Research Institute · R01 · FY2003 · EY
Memory CD8 T Cell Responses After Multiple Antigen Encounters
$372,000Vladimir P Badovinac · University Of Iowa · R01 · FY2009 · AI
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
$371,981Robert M Prins · University Of California Los Angeles · P50 · FY2018 · CA
SPORE in Lymphoma
$371,941Helen E Heslop · Baylor College Of Medicine · P50 · FY2009 · CA
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers
$371,925Matthias Stephan · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA
Antibody Gene Therapy for Methamphetamine Abuse
$371,911Eric C Peterson · Univ Of Arkansas For Med Scis · R01 · FY2014 · DA
Microglia Mediated Inflammation in the Diabetic Retina
$371,872Astrid E Cardona · University Of Texas San Antonio · R01 · FY2020 · EY
Role of cross-presentation by APCs in modulating graft-versus-leukemia responses
$371,870Pavan Reddy · University Of Michigan At Ann Arbor · R01 · FY2011 · HL
Research Training in Immunology
$371,804David H Sherr · Boston University Medical Campus · T32 · FY2012 · AI
Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling
$371,746Seyed Javad Mirhassani Moghaddam · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA
HSP 110 and its role in cancer therapy
$371,726John R. Subjeck · Roswell Park Cancer Institute Corp · R01 · FY2009 · CA
Macrophage-based ovarian cancer immunotherapy
$371,717Fiona E Yull · Vanderbilt University · R01 · FY2017 · CA
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer
$371,700David B. Solit · Sloan-Kettering Inst Can Research · P50 · FY2023 · CA
Role of TLR9 in Lung Antibacterial Host Defense
$371,680Theodore J. Standiford · University Of Michigan At Ann Arbor · R01 · FY2011 · HL
Role of TLR9 in Lung Antibacterial Host Defense
$371,680Theodore J. Standiford · University Of Michigan At Ann Arbor · R01 · FY2009 · HL
Role of TLR9 in Lung Antibacterial Host Defense
$371,680Theodore J. Standiford · University Of Michigan At Ann Arbor · R01 · FY2008 · HL
Role of TLR9 in Lung Antibacterial Host Defense
$371,680Theodore J. Standiford · University Of Michigan At Ann Arbor · R01 · FY2010 · HL
Role of TLR9 in Lung Antibacterial Host Defense
$371,680Theodore J. Standiford · University Of Michigan At Ann Arbor · R01 · FY2007 · HL
Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer
$371,660Abhijit Patel · Yale University · R01 · FY2019 · CA
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function
$371,660Scott I. Abrams · Roswell Park Cancer Institute Corp · R01 · FY2014 · CA
T32 Urologic Oncology Research Training Program
$371,627Brett Stewart Carver · Sloan-Kettering Inst Can Research · T32 · FY2023 · CA
Role of cross-presentation by APCs in modulating graft-versus-leukemia responses
$371,626Pavan Reddy · University Of Michigan At Ann Arbor · R01 · FY2012 · HL
Integration of neo-antigen vaccines and immune checkpoint therapy
$371,552Elizabeth Marion Jaffee · Johns Hopkins University · P01 · FY2024 · CA
Targeted delivery of multimodal therapy for reducing prostate cancer disparity
$371,500Runhua Runa Liu · University Of Alabama At Birmingham · R01 · FY2023 · CA
Efficient Delivery of Plasmid DNA to Achieve Appropriate Transgene Expression
$371,451Richard Heller · Old Dominion University · R01 · FY2015 · CA